ASHG 2026 has ended. This guide stays up as the record of who was there. Next: ASHG 2027, Oct 26–30, 2027 in Nashville
Zevra Therapeutics at ASHG 2026
Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website
Zevra Therapeutics brings 1 presentation to ASHG 2026 in Montréal, and exhibits at Booth 1302. Its program centres on rare-disease therapeutics and evidence from patient access programs at this meeting. Its presentation examines NPC1 genotypes in a US early access program for Niemann-Pick disease type C.
| Organization | ASHG 2026 Attendance |
|---|---|
Zevra Therapeutics Boston, Massachusetts | 1 presenter |
Zevra develops and commercializes therapeutics for rare diseases, serving patients with limited or no treatment options.
| Booth Exhibiting at Booth 1302 Wed, Oct 219:30am–4:30pmThu, Oct 229:30am–6:15pmFri, Oct 239:30am–4:30pm Poster Fri Oct 23 2:30 pm Analysis of NPC1 Genotypes: Findings from the US Arimoclomol Early Access Program for Niemann-Pick Disease Type C Lysosomal diseasesBrain/nervous systemNervous system |
Find decision makers at Zevra Therapeutics
Tell us what you sell and we’ll find the people at Zevra Therapeutics most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction